Hattinger Claudia M, Vella Serena, Tavanti Elisa, Fanelli Marilù, Picci Piero, Serra Massimo
Pharmacogenomics & Pharmacogenetics Research Unit of the Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Via di Barbiano 1/10, I-40136 Bologna, Italy.
Laboratory of Experimental Oncology, Orthopaedic Rizzoli Institute, Via di Barbiano 1/10, I-40136 Bologna, Italy.
Pharmacogenomics. 2016 Dec;17(18):2097-2114. doi: 10.2217/pgs-2016-0116. Epub 2016 Nov 24.
Second-line treatment of high-grade osteosarcoma (HGOS) patients is based on different approaches and chemotherapy protocols, which are not yet standardized. Although several drugs have been used in HGOS second-line protocols, none of them has provided fully satisfactory results and the role of rescue chemotherapy is not well defined yet. This article focuses on the drugs that have most frequently been used for second-line treatment of HGOS, highlighting the present knowledge on their mechanisms of action and resistance and on gene polymorphisms with possible impact on treatment sensitivity or toxicity. In the near future, validation of the so far identified candidate genetic biomarkers may constitute the basis for tailoring treatment by taking the patients' genetic background into account.
高级别骨肉瘤（HGOS）患者的二线治疗基于不同的方法和化疗方案，这些方法和方案尚未标准化。尽管几种药物已用于HGOS二线方案，但它们均未取得完全令人满意的结果，且挽救性化疗的作用尚未明确界定。本文重点关注最常用于HGOS二线治疗的药物，突出目前对其作用机制、耐药性以及可能影响治疗敏感性或毒性的基因多态性的认识。在不久的将来，对迄今已鉴定出的候选基因生物标志物进行验证，可能会成为基于患者遗传背景进行个性化治疗的基础。
